GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results without prescriptions ...

Pharmaceuticals and Medical Devices Agencies (PMDA) receives the non-clinical safety studies following Good Laboratory Practice (GLP) for the marketing authorization of medical products. Here we ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...

GLP was the largest shareholder in GCP International prior to Ares’ acquisition of GCP International on March 1, 2025 and continues to own digital infrastructure assets across major ...

For patients with diabetes, exposure to GLP-1 RAs is associated with an increased risk for incident neovascular AMD development.

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.